Malignancy is an important cause of death in transplant recipients. Cutaneous squamous cell carcinoma (cSCC) causes significant morbidity and mortality as 30% of transplant recipients will develop cSCC within 10 years of transplantation. Previously we have shown that high numbers of regulatory T cells (Tregs) are associated with the development of cSCC in kidney transplant recipients (KTRs). Demethylation analysis of the Tregspecific demethylated region (TSDR) provides a more accurate association with cSCC risk after transplantation. Age, gender and duration of immunosuppression matched KTRs with (n ¼ 32) and without (n ¼ 27) cSCC, were re-analyzed for putative clinical and immunological markers of cancer risk. The proportion of FOXP3þ CD4þ cells was higher in the population with a previous SCC. Major T cell subsets remained stable over time; although B cell, CD8 and CD4 subpopulations demonstrated age-related changes. TSDR methylation analysis allowed clarification of Treg numbers, enhancing the association of high Treg levels in KTRs with cSCC compared to the cSCC-free cohort. These data validate and expand on previous findings in long-term KTRs, and show that immune markers remain stable over time. TSDR demethylation analysis provides a more accurate biomarker of cancer posttransplantation.
Introduction
Transplantation is the treatment of choice for individuals with end-stage kidney failure, with current 1-year graft survival rates greater than 90% (1) . Unfortunately, good short-term outcomes have not been accompanied by improvements in long-term graft and patient survival (2) . Side effects of nonspecific immunosuppression can result in nephrotoxicity and significant morbidity and mortality from cardiovascular disease (3), infection (4) and malignancy (5) . Morbidity and mortality from malignancy is an increasing problem and is now the commonest cause of death in transplant recipients in Australia and New Zealand (6) . Furthermore, 10-year incidence of malignancy in UK organ transplant recipients is twice the rate of the general population (7) . Although there is substantial variation in the standardized incidence ratio of different cancers posttransplantation, the greatest prevalence is seen in cutaneous squamous cell carcinoma (cSCC) (7) (8) (9) . Organ transplant recipients are 200 times more likely to develop a cSCC than the general population (10) . cSCC grow more rapidly and metastasize more readily in kidney transplant recipients (KTRs) resulting in increased morbidity and mortality (11, 12) . Mechanisms underlying the substantial increase in cSCC prevalence posttransplantation include skin type, ultra-violet light exposure, chronic human papilloma virus colonization and type and duration of immunosuppression (11) . The impact of immunosuppression suggests that modulation of the immune system plays an important role in the development of cancers posttransplantation. Analysis of immune cell subsets to identify individuals at increased risk of cancer posttransplantation has proved informative. Low CD4 lymphocyte counts may predict cancer risk (13) , while other studies have focused on immune-regulatory or effector cell populations. Increased numbers of regulatory T cells (Tregs) in the peripheral circulation is associated with a poor prognosis in cancer in the general population (14, 15) . Previously we have shown that high numbers of Treg (FOXP3 þ CD4 þ CD25 þ CD127 low ) and low numbers of natural killer (NK) cells are associated with an increased risk of developing cSCC posttransplantation (11) . Tregs were characterized by the expression of FOXP3, but subsequently it has become clear that FOXP3 
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Patients
The study re-recruited KTRs with and without histologically diagnosed cSCC who had been previously matched for age (AE5 years), gender and time on immunosuppression (AE5 years). Patients with second or subsequent grafts had the duration of immunosuppression summed. KTRs without cSCC could have cSCC in situ (Bowen's disease), basal carcinoma or keratoacanthomas. KTRs with skin types I-IV were selected because cSCC predominantly affects fair-skinned populations.
All 106 transplant patients previously recruited were invited for rerecruitment, 74 of these patients (69.8%) were identified as still alive with a functioning graft (Figure 1 ). The study was approved by a multi-center ethics committee and performed according to Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for observational studies. Written informed consent was obtained from all patients who participated. Three KTRs declined to be assessed, eight KTRs had been transferred to hospitals away from the Oxford University Hospitals NHS Trust and five KTRs we were lost to follow-up. At the end of rerecruitment in March 2013, 32 KTRs with SCC and 26 KTRs without SCC had been re-recruited. Case records and the hospital histopathology database were reviewed, and demographic, transplantation and histopathologic variables were recorded. Tumors that were defined as re-excision or as arising from scar tissue were excluded.
Immune phenotyping
Peripheral blood was collected from KTRs during at routine clinical follow-up.
Patients were asked about current skin lesions to ensure blood was not taken during active disease. Peripheral blood mononuclear cells (PBMCs) were separated from whole blood by standard centrifugation and Ficoll techniques within a median of 40 min (range 30-100 min) of venesection. Lymphocytes were stained as described previously and analyzed via flow cytometry (11) . Absolute counts for cell populations identified were calculated using total lymphocyte count from routine hematology laboratory results and the proportion of each cell type in the lymph gate from flow cytometry data. Immune phenotyping was postponed when the following were present: fever >37.88C or oral or intravenous antibiotic or antiviral therapy current or completed with 2 weeks. Patients who were admitted 1 week after immune phenotyping for suspected or confirmed infection were re-assessed during a clinically quiescent period. . Genomic DNA from whole isolated PBMCs was extracted with the QIAamp DNA blood mini kit (Qiagen, Hilden, Germany). A minimum of 60 ng bisulfite-treated (EpiTect; Qiagen) genomic DNA was used in a real-time polymerase chain reaction (PCR) to quantify the FOXP3 TSDR. Real-time PCR was performed in a final reaction volume of 20 mL containing 10 mL FastStart universal probe master (Roche Diagnostics, Mannheim, Germany), 50 ng/mL lamda DNA (New England Biolabs, Frankfurt, Germany), 5 pmol/mL methylation or nonmethylationspecific probe, 30 pmol/mL methylation or nonmethylation-specific primers and 60 ng bisulfite-treated DNA or a respective amount of plasmid standard. The samples were analyzed in triplicate on an ABI 7500 cycler (Life Technologies Ltd, Carlsbad, CA).
Statistical analysis
All statistical analysis was performed using the statistical software SPSS 16 (SPSS, Chicago, IL) and GraphPad Prism 5 (GraphPad Software, San Diego, CA). A value of p < 0.05 was considered significant in all statistical tests.
Results
A total of 58 (55.7% of original study cohort) KTRs were recruited (n ¼ 32 KTRs with cSCC; n ¼ 26 without cSCC). The mean follow-up time for all patients re-recruited was 1595.1 days (1135-2025) since initial immune phenotype analysis. In the SCC cohort 73% developed a further cSCC during the follow-up period, with 50% developing more than one cSCC. In contrast only 4% of the non-cSCC cohort developed a cSCC during the same period. A total of 21 (19.8%) patients had died since initial recruitment (Figure 1 ). Furthermore 11 KTRs (10.4%) had lost their graft and 16 (15.1%) were lost to follow-up (Figure 1 ). The group with and without cSCC remained well matched for age, sex, number of transplants, HLA mismatches and duration of immunosuppression (Table 1) . We found no significant difference between the type of immunosuppression between the cSCC and non-cSCC cohorts, although four of the cSCC group were on an mTOR inhibitor, and three of the four had been maintained on an mTOR inhibitor throughout the study period. The mean (AESD; range) Cyclosporin trough level at time of second sampling was 79 ng/mL (AE27; 30-148): mean Sirolimus trough level 4.8 ng/mL (AE1.0; <3-5.6): mean Tacrolimus trough level 7.4 ng/mL (AE4.0; 4.6-12).
We found a significant increase in the proportion of FOXP3þ CD4þ T cells with a previous cSCC ( Figure 3D ). Second, we assessed the stability of the main lymphocyte subsets in the current cohort and compared the data with that from matched patients in the original cohort (Figure 2) . We found no differences in the proportion of CD8 or NK cells between the two groups. There was a small but significant rise in the number of CD4þ cells over the follow-up period (p ¼ 0.03), and a significant reduction in the proportion of B cells (p ¼ 0.006). In the analysis of CD4þ and CD8þ lymphocyte subgroups we found age-typical changes in the proportions of na€ ıve (p < 0.001), central memory (Cm; p < 0.001), effector memory (Em; p < 0.001), effector memory RA (EmRA; p < 0.001) and CD8þ CD28À regulatory cells (p < 0.001) (19) . We observed a nonsignificant rise in the proportion of CD4þ FOXP3þ cells.
The utilization of the methylation status of the TSDR region to identify true Tregs identified a significant increase in the proportion of CD4þ TSDR-demethylated cells in patients who had previously developed an cSCC (p ¼ 0.03; Figure 3) . KTRs who had never developed a nonmelanoma skin cancer had a significantly lower number of TSDR-demethylated CD4þ cells than those who have had a previous cSCC (p ¼ 0.008). Interestingly, the proportion of CD4þ lymphocytes that were FOXP3þ was significantly less than the 
TSDR Is SCC Marker in KTRs
proportion of TSDR-demethylated CD4þ cells. Moreover, the ratio of FOXP3þ/TSDR-demethylated CD4þ lymphocytes was significantly lower in patients who had Cyclosporin A in their drug regimen compared with those who were calcineurin inhibitor (CNI) free (p < 0.001; Figure 3 ). We explored the potential predictive value of FOXP3þ CD4þ T cells and CD4þTSDR-demethylated cells for cSCC risk using receiver operator characteristic analysis. The areas under the curve were 0.68 for % FOXP3þ CD4þ T cells and 0.70 for % CD4þ TSDR-demethylated cells, respectively.
Conclusion
This is the first study to confirm stability of immune phenotype of peripheral blood leukocytes in long-term KTRs during follow-up, and the persistence of a different immune phenotype in KTRs with and without cSCC. KTRs that had previously developed a cSCC continued to have a higher proportion of FOXP3þ CD4þ T-lymphocytes and a reduced number of CD8þ Cm T cells than those who were cSCC free, reinforcing the observations made in the initial study cohort (11) . The high death rate during the recruitment interval of the two cohorts emphasizes the increasing observation of the impact of death with a functioning graft on long-term outcome (20) .
An important finding of this study is the consistency of key components of the immune phenotype over time in chronically immunosuppressed patients. This strengthens the potential use of immune phenotype as a biomarker of cancer risk posttransplantation. Importantly, the proportion of FOXP3þ CD4þ cells remains stable, making it suitable for use as a biomarker for cancer posttransplantation. We have assumed that the number of TSDR-demethylated cells is likely to remain consistent in line with the total Treg numbers. It would be interesting to prospectively reassess the stability of TSDR demethylation in Tregs, in this or a similar cohort of transplant patients with cSCC to confirm this assumption in the future. We found a large variation in the proportion of CD8 and CD4 subsets, as well as CD8þ CD28À regulatory cells, which we mainly attribute to aging (19) .
This study demonstrates that patients who have previously developed a cSCC have increased numbers of FOXP3þ 
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CD4þ T cells, which may prove to be a useful marker of skin cancer in transplant recipients. This observation is supported by several other studies, as well as FOXP3 being linked to cancer risk and outcome in the general population (11, (21) (22) (23) (24) . It is important to recognize that there are other potential etiological factors, which could interact with the host immune phenotype such as a potential effect of chronic beta-human papilloma virus colonization (25) . While studies on mice have shown FOXP3 to be a direct marker of Tregs, FOXP3 has also been shown to be up-regulated upon activation of human nonTreg effector cells (16, 17) . The up-regulation of FOXP3 upon activation of effector cells in the human results in an over-representation of Tregs, particularly in transplant patients due to chronic immune stimulation. Utilization of the TSDR methylation status allows identification of true Tregs (18) . We have shown that TSDR-demethylated CD4þ lymphocytes amplify the association of higher proportions of Tregs in KTRs with cSCC compared to those without cancer. Interestingly, we found that the proportion of FOXP3þ cells was less than the proportion of TSDR-demethylated CD4þ cells. One previous study utilizing a ratio of FOXP3þ to TSDR-demethylated CD4þ cells showed that pediatric liver transplant recipients taking a CNI had a ratio <1 compared to those on a CNI-free regimen (26) . Here, we replicate these findings, with patients on CyA having a FOXP3:TSDR ratio of <1, significantly lower than those on a CNI-free regimen. 
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